Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
17.15 USD -1.27% Intraday chart for Entrada Therapeutics, Inc. +21.37% +13.65%
Jun. 25 HC Wainwright Cuts Entrada Therapeutics Price Target to $18 From $20, Maintains Buy Rating MT
Jun. 24 Entrada Therapeutics Signs Securities Purchase Agreement of 3.4 Million Common Shares in Registered Direct Offering MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Cuts Entrada Therapeutics Price Target to $18 From $20, Maintains Buy Rating
MT
Entrada Therapeutics Signs Securities Purchase Agreement of 3.4 Million Common Shares in Registered Direct Offering
MT
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics Announces $100 Million Registered Direct Offering
GL
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
GL
Entrada Therapeutics, Inc Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
CI
Transcript : Entrada Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 04:00 PM
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GL
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing
MT
Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing
MT
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Entrada Therapeutics Reports First Quarter 2024 Financial Results
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. News Entrada Therapeutics, Inc.